SCHEMBL15052030

SCHEMBL15052030

CC(=O)Nc1cc(-n2cc(-c3nc[nH]n3)c(-c3ccccc3Cl)n2)c(F)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.36
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35
ABL1 P00519 8/20 0.34
HTR5A P47898 1/20 0.34
DGAT2 Q96PD7 2/20 0.33
LIMK1 P53667 1/20 0.33
TGFBR1 P36897 3/20 0.33
CCNE2 O96020 1/20 0.33
EGFR P00533 1/20 0.33
CDK1 P06493 1/20 0.33
CDK4 P11802 1/20 0.33
SRC P12931 1/20 0.33
CCND1 P24385 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
KDR P35968 1/20 0.33
CCNA1 P78396 1/20 0.33
PTK2 Q05397 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15050840 0.90 ABL1 (0.36) ABL1LIMK1CCNE2EGFRCDK1
SCHEMBL15051720 0.90 ABL1 (0.47) ABL1
SCHEMBL15072353 0.90 ABL1 (0.34) ABL1DGAT2LIMK1CCNE2EGFR
SCHEMBL15051313 0.84 ABL1 (0.40) RORCABL1CDK1CDK4CDK2
SCHEMBL15051059 0.83 JAK2 (0.40) LIMK1TGFBR1
SCHEMBL15072383 0.82 MAPK1 (0.36) ABL1TDP1
SCHEMBL15051877 0.82 ABL1 (0.36) ADORA3ABL1EGFRKDR
SCHEMBL15051487 0.81 ABL1 (0.47) ABL1
SCHEMBL15051492 0.80 PIK3C3 (0.38) RORCTGFBR1KDR
SCHEMBL15051295 0.80 RAB9A (0.35) ADORA3ABL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165464-A1 HETEROARYLS AND USES THEREOF PIK3C2B, PI4KB, PIK3R4 RORC 1271/4885ADORA3 2319/4885ADORA2A 2938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.